Benefit-risk analysis of adalimumab versus methotrexate and placebo in the treatment of moderate to severe psoriasis: Comparison of adverse event–free response days in the CHAMPION trial

✍ Scribed by Kristian Reich; James Signorovitch; Karthik Ramakrishnan; Andrew P. Yu; Eric Q. Wu; Shiraz R. Gupta; Yanjun Bao; Parvez M. Mulani

• Book ID: 116586660
• Publisher: Elsevier Science
• Year: 2010
• Tongue: English
• Weight: 407 KB
• Volume: 63
• Category: Article
• ISSN: 1097-6787
• DOI: 10.1016/j.jaad.2009.12.029